<DOC>
	<DOCNO>NCT02265666</DOCNO>
	<brief_summary>The objective present study investigate relative bioavailability BIIL 284 BS Tablet FF comparison tablet C dose 5 mg standard breakfast healthy male volunteer</brief_summary>
	<brief_title>Relative Bioavailability , Safety Tolerability Two Tablet Formulations BIIL 284 BS</brief_title>
	<detailed_description />
	<criteria>All participant healthy male Age range 21 50 year BrocaIndex : within + 20 % normal weight In accordance Good Clinical Practice ( GCP ) local legislation volunteer suppose give write informed consent prior admission study Any finding medical examination ( include blood pressure , pulse rate ECG ) deviate normal clinical relevance Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Diseases central nervous system ( epilepsy ) psychiatric disorder History orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator Intake drug long halflife ( &gt; 24 hour ) within least one month less ten halflives respective drug enrollment study Use drug might influence result trial ( &lt; = one week prior administration trial ) Participation another trial investigational drug ( &lt; = two month prior administration trial ) Smoker ( &gt; 10 cigarette 3 cigar 3 pipes/day ) Inability refrain smoke study day Alcohol abuse ( &gt; 60g/day ) Drug abuse Blood donation ( &gt; = 100 mL within four week prior administration trial ) Excessive physical activity ( within last week study ) Any laboratory value outside reference range clinical relevance</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>